Skip to content

IRadimed

US · IRMD #3190 by market cap
81.02 -0.24 -0.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 81.06 -0.25%
After-hours 81.02 0.00%
102.0776.6885.352026-05-182026-11-13
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IRMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +0.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 4.6% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 43.3x Better than 12%
Forward P/E 38.2x Better than 11%
Price / Sales 12.2x Better than 9%
P/E vs own 5-yr range 69th pctl Better than 39%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 16.3% Better than 78%
Net income CAGR (3Y) 20.6% Better than 73%
Free cash flow CAGR (3Y) 26.5% Better than 71%
Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 76.7% Better than 88%
Operating margin 31.2% Better than 90%
Net margin 26.8% Better than 86%
Return on equity 24.8% Better than 83%
Return on invested capital 23.0% Better than 93%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -2.8% Better than 67%
6-month return -7.1% Better than 44%
12-month return (ex latest month) -3.0% Better than 31%
Distance below 52-week high 24.2% Better than 52%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 8.0x Better than 92%
Debt to assets 0.0% Better than 100%
Free cash flow / net income 73.5% Better than 23%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.11%
1M -4.80%
3M -1.85%
6M +0.56%
YTD -11.69%
1Y +2.40%
3Y +114.45%
5Y +133.26%

Key statistics

Price & volume

Prev close
81.26
Open
80.61
Day range
80.61 - 82.11
Avg price
81.29
Volume
101.30K
Turnover
8.24M
Amplitude
1.84%
52-week range
76.17 - 106.95

Valuation

P/E
46.30
P/E (TTM)
43.33
P/B
9.73
EPS
1.75
Net profit
22.38M
Net assets
106.45M

Share structure

Market cap
1.04B
Float cap
675.01M
Shares out
12.79M

Dividend & listing

Dividend (TTM)
0.77
Listing date
--
52-week range 16% of range
76.17 106.95

24.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.12M net over the window

Short interest

Shares short
590.05K
As of
2026-10-30

Frequently asked questions

What is the current stock price of IRadimed (IRMD)?

IRadimed last traded at 81.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is IRadimed's market cap?

About 1.04B.

What is the P/E ratio of IRadimed?

The trailing twelve-month P/E is 43.33, above its own 5-year average of 43.22 — toward the top of its historical range (68.87% percentile). See the Valuation tab for the full history.

Does IRadimed pay a dividend?

Yes. The trailing dividend yield is 0.95%. The 2025 payout was up 162.2% from 2024. See the Dividends tab for the full payment history.

Is IRadimed a buy according to analysts?

The consensus of 1 analysts is a Hold rating, with an average 12-month price target of 120.00, which implies 48.1% upside from the current price. This is not investment advice.

What is IRadimed's StockVane Quant Rating?

The StockVane Momentum strategy currently rates IRadimed a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

IRadimed discussion 0 comments

Add a comment